Home Cart Sign in  
Chemical Structure| 86030-08-2 Chemical Structure| 86030-08-2

Structure of BTB-1
CAS No.: 86030-08-2

Chemical Structure| 86030-08-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BTB1 an ATP-competitive and selective inhibitor of the mitotic motor protein Kif18A with IC50 value of 1.7 μM.

Synonyms: NSC 156750; NSC 658180

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BTB-1

CAS No. :86030-08-2
Formula : C12H8ClNO4S
M.W : 297.71
SMILES Code : O=[N+](C1=CC(Cl)=CC=C1S(=O)(C2=CC=CC=C2)=O)[O-]
Synonyms :
NSC 156750; NSC 658180
MDL No. :MFCD00052250
InChI Key :VZDUQPHKUBZMLW-UHFFFAOYSA-N
Pubchem ID :291461

Safety of BTB-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BTB-1

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 10 µM 12 h To evaluate the effect of BTB-1 on IAV-induced cytopathic effect. BTB-1 treatment significantly reduced the IAV-induced cytopathic effect. PMC7214149
HEK293 cells 5 or 10 µM 12 or 24 h To evaluate the effect of BTB-1 on IAV-induced cytopathic effect. BTB-1 treatment significantly reduced the IAV-induced cytopathic effect. PMC7214149
MDCK cells 5 or 10 µM 10 or 12 or 15 h To evaluate the effect of BTB-1 on IAV-induced cytopathic effect. BTB-1 treatment significantly reduced the IAV-induced cytopathic effect. PMC7214149

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice IAV infection model Intranasal administration 3 mg/kg Administered at 10 minutes, 3 hours, and 6 hours post-infection To evaluate the protective effect of BTB-1 on IAV-infected mice. BTB-1 treatment significantly improved the survival rate and reduced weight loss in infected mice. PMC7214149

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.36mL

0.67mL

0.34mL

16.79mL

3.36mL

1.68mL

33.59mL

6.72mL

3.36mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories